The corporate clash between Pfizer and Starboard Value heated up on Thursday when the activist investment firm pressed the ...

Pfizer said on Thursday a combination of its drugs, Talzenna and Xtandi, helped prolong the lives of patients with a type of ...

The FDA approved Pfizer’s Hympavzi, which can be an alternative to intravenous infusions often administered multiple times a ...

Starboard said a former CEO and CFO had assisted in its activist campaign but then were pressured to express support for the ...

Starboard Value has asked Pfizer to set up a special committee to investigate allegations that two of its former senior ...

The monoclonal antibody is the first non-factor, once-weekly treatment approved in the United States for hemophilia B.

Some misleading narratives about Bourla’s leadership that have been put forward have been distinctly unfair,' write Jeff ...

Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA ...

In prostate cancer, Pfizer’s Talzenna already holds the broadest FDA approval within the PARP inhibitor class. | In prostate ...

"We have decided not to be involved in the efforts of Starboard Value regarding Pfizer. We are fully supportive of Pfizer ...

Hedge fund Starboard Value's activist campaign targeting Pfizer (PFE) divides Wall Street, with analysts questioning the ...

The new drug would allow patients to produce the needed clotting protein for an extended period, reducing the need for ...